topiramate treatment with haloperidol in chronic tic disorder

Comparing the effectiveness of topiramate treatment with haloperidol in chronic tic disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230803059021N1

Enrollment

Registered

2023-08-10

Start date

2023-08-23

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic tic disorder. Chronic motor or vocal tic disorder

Interventions

Intervention 1: Intervention group: Treatment with haloperidol manufactured by Subhan Daru company in the form of 0.25 to 8 mg daily for 2 months. Intervention 2: Intervention group: Treatment with to

Eligibility

Sex/Gender

All

Age

6 Years to 12 Years

Inclusion criteria

Inclusion criteria: parental informed consent DSM-V criteria for chronic tic disorder age between 6 and 12

Exclusion criteria

Exclusion criteria: Presence of major medical disorders such as epilepsy, diabetes, heart and kidney diseases mental retardation Hypersensitivity to topiramate and haloperidol The presence of concomitant psychiatric disorders that require drug intervention History of long QT syndrome, cardiac arrhythmia, kidney stones and concurrent use of carbonic anhydrase inhibitor drugs

Design outcomes

Primary

Measure	Time frame
Tic. Timepoint: before treatment and 1 month after and 2 month after. Method of measurement: Yale Global Tic Severity scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFaime Rezaie

Esfahan University of Medical Sciences

rezaeedr022@gmail.com+98 31 3668 8138

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026